Riccardo Lunardi

Externautics SpA provides biotechnology research and development services. The firms designs and manages platforms that identify and develop novel diagnostic and therapeutic markers for oncology applications. Its technology approach is based on the screening of libraries of polyclonal antibodies and recombinant proteins, generated from the corresponding human gene library of the poorly known membrane and secreted proteins. It focuses on the identification of membrane-exposed or serum circulating proteins whose presence associate to the frequent types of human tumors. The company was founded by Guido Grandi in 2007 and is headquartered in Siena, Italy.

Externautics SpA provides biotechnology research and development services. The firms designs and manages platforms that identify and develop novel diagnostic and therapeutic markers for oncology applications. Its technology approach is based on the screening of libraries of polyclonal antibodies and recombinant proteins, generated from the corresponding human gene library of the poorly known membrane and secreted proteins. It focuses on the identification of membrane-exposed or serum circulating proteins whose presence associate to the frequent types of human tumors. The company was founded by Guido Grandi in 2007 and is headquartered in Siena, Italy.

Externautics SpA provides biotechnology research and development services. The firms designs and manages platforms that identify and develop novel diagnostic and therapeutic markers for oncology applications. Its technology approach is based on the screening of libraries of polyclonal antibodies and recombinant proteins, generated from the corresponding human gene library of the poorly known membrane and secreted proteins. It focuses on the identification of membrane-exposed or serum circulating proteins whose presence associate to the frequent types of human tumors. The company was founded by Guido Grandi in 2007 and is headquartered in Siena, Italy.